Epic Sciences’ multi-technology approach offers Comprehensive Cancer Profiling, measuring CTCs and ctDNA TSO500 from a single blood draw. CTCs and ctDNA liquid biopsies enable complementary information for clinical decisions, allowing for diagnosis, accurate prognosis, therapeutic target selection, as well as monitoring response and resistance to treatment.
Their enrichment-free approach with the CTC rare cell detection platform reveals both genotype and phenotype, providing a unique view into disease heterogeneity. Epic Sciences’ partners with biopharma companies to improve drug development with CTC technology and ctDNA TSO500 analysis for a liquid biopsy that is both minimally invasive and highly accurate.
This presentation covers:
- How a multi-technology approach including CTCs and ctDNA TSO500 from a single blood draw can improve drug development efforts for biopharma companies.
- How Comprehensive Cancer profiling can provide insight into patient identification using CTCs and ctDNA TSO500 biomarker analysis in lieu of difficult to obtain tissue biopsy.
- Expanded clinical applications, including how Comprehensive Cancer Profiling can identify emerging resistant mechanisms and whether those are targetable by approved drugs or eligible for clinical trials.
Download the presentation slides or watch the recorded webinar.
Related Insights
Reproducibility Challenges in an era of Massive Data
Presented at the MCBIOS & MAQC 2021 Joint Conference
A Verified Genomic Reference Sample for Assessing Performance of Cancer Panels Detecting Small Variants of Low Allele Frequency
Presented at the MCBIOS & MAQC 2021 Joint Conference
Unexpected Impacts to Library Complexity After DNA and RNA Library Preparation in Illumina Next Generation Sequencing
Presented at the MCBIOS & MAQC 2021 Joint Conference
Immune Landscape Signatures for Characterization of Tumor Microenvironment and Response to Therapy
Gene expression and analysis for detection of 38 Immune Landscape Signatures
Using Gene Signature Methodologies to Strengthen Immuno-Oncology Trials
Genomic technologies that empower and enhance immuno-oncology trials
Laboratory Solutions for Hepatitis B (HBV) Clinical Trials
Insight brief by Joseph Sebastian, Ph.D., Scientific Advisor, Infectious & Liver Diseases
Enabling blood sample prep for single cell sequencing in clinical research
The Role of Genomics in Clinical Trials with Patrick Hurban
I-O clinical development podcast series
IQVIA Laboratories Corporate Brochure
A global drug discovery and development laboratory services organization
Evaluating and Implementing SARS-CoV-2 PCR Tests for Diagnostic and Clinical Trial Use
AAPS 2020 COVID-19 Workshop: Current Pharmaceutical Developments for Cures and Prevention
